Cargando...
Co-Targeting of JNK and HUNK in Resistant HER2-Positive Breast Cancer
Strategies for successful primary treatment of HER2-positive breast cancer include use of the HER2 inhibitors trastuzumab or lapatinib in combination with standard chemotherapy. While successful, many patients develop resistance to these HER2 inhibitors indicating an unmet need. Consequently, curren...
Guardado en:
| Publicado en: | PLoS One |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Public Library of Science
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4821489/ https://ncbi.nlm.nih.gov/pubmed/27045589 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0153025 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|